Monocyte/Granulocyte to Lymphocyte ratio and the MELD score as Prognostic Predictors for Early Recurrence of Hepatocellular Carcinoma after Trans-Arterial Chemoembolization.

Monocyte/Granulocyte to Lymphocyte ratio and the MELD score as Prognostic Predictors for Early Recurrence of Hepatocellular Carcinoma after Trans-Arterial Chemoembolization. Br J Biomed Sci. 2018 Jul 11; Authors: Elalfy H, Besheer T, El-Maksoud MA, Farid K, Elegezy M, El Nakib AM, El Aziz MA, El-Khalek AA, El-Morsy A, Elmokadem A, Elsamanoudy AZ, El-Bendary MA Abstract BACKGROUND: The first-line treatment option for intermediate-stage hepatocellular carcinoma is transarterial chemoembolization. Certain blood indices, such as lymphocyte/monocyte ratio (LMR), lymphocyte count, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte-granulocyte/lymphocyte ratio (MGLR) and red blood cell distribution width (RDW) are prognostic biomarkers in certain diseases. The model for end-stage liver disease (MELD) and Child-Turcotte-Pugh (CTP) scores have been designed for patients with cirrhosis waiting for liver transplantation and in patients with hepatocellular carcinoma. We hypothesised possible roles for these blood indices, and the clinical MELD and CTP scores as prognostic predictors for early recurrence of hepatocellular carcinoma after transarterial chemoembolization. METHODS: Routine laboratory indices determined the NLR, LMR, MGLR, RDW, PLR, and MELD the CTP scores in 147 patients. Sensitivity and specificity of the indices for hepatocellular carcinoma recurrence 36 months after transarterial chemoembolization were estimated by receiv...
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research

Related Links:

Kidney transplantation is the best treatment for patients with end-stage renal disease (ESRD) because of a significant survival benefit conferred compared to patients who remain on haemodialysis.1 Although the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in patients with ESRD has significantly declined over time, it remains at least 4-times higher than in the general population.2,3 Chronic HCV or HBV infection can result in chronic liver disease, cirrhosis, and hepatocellular carcinoma4 –6 and increase the risk of chronic kidney disease (CKD).
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Research Article Source Type: research
Authors: Wei L, Huang YH Abstract INTRODUCTION: Within the past decade, antiviral treatment for chronic hepatitis C virus (HCV) infection has evolved from interferon (IFN)-based regimens to IFN-free oral direct-acting antiviral agents (DAAs). However, data on long-term outcomes in HCV patients treated by DAAs are limited and complex. This review summarizes the literature on long-term outcomes in patients with chronic HCV infection who received IFN-based and DAA treatment. Areas covered: Original studies and meta-analyses reporting data on the impacts of IFN- and DAA-based treatments on late relapse, liver fibrosis/...
Source: Expert Review of Anti-Infective Therapy - Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research
Background: Hepatocellular carcinoma (HCC) accounts for 90% of primary hepatic malignancies. With the exception of chronic hepatitis B (CHB), other etiologies of chronic liver disease require progression to cirrhosis before HCC development. Case reports have described HCC in noncirrhotic patients with hepatitis C (HCV) and nonalcoholic fatty liver disease. Goal: The aim of this study was to determine the prevalence of patients without cirrhosis and CHB who developed HCC among a large cohort of HCC patients and to identify independent variables that are associated with no cirrhosis among patients with HCC. Study: Fr...
Source: Journal of Clinical Gastroenterology - Category: Gastroenterology Tags: LIVER, PANCREAS & BILIARY TRACT: Original Articles Source Type: research
CONCLUSION: Women with cirrhosis on the liver transplant waitlist have more hospitalizations and inpatient days in one year compared with men, suggesting that the experience of cirrhosis differs between men and women, despite similar baseline illness severity. Future studies should explore gender-specific vulnerabilities to help explain waitlist disparities. PMID: 30833803 [PubMed - in process]
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research
Authors: Hsu CS, Kao JH Abstract INTRODUCTION: Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength, which is commonly associated with various chronic diseases, including chronic liver diseases. Growing lines of evidence indicate that sarcopenia not only correlates with the clinical outcomes and survival of patients undergoing liver transplant, but also serves as a prognostic factor for candidates of liver transplantation and patients with hepatocellular carcinoma. Areas covered: In this review, we conducted a narrative review and search of literature from ...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
Authors: Bertot LC, Adams LA Abstract INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and is associated with hepatocellular carcinoma (HCC), the most frequent malignant liver tumor. The increasing prevalence of obesity and diabetes is influencing the epidemiology of HCC with the most dramatic increases in NAFLD-related HCC seen in Western countries. Although cirrhosis is the major risk factor for HCC in NAFLD, there is increasing recognition that NAFLD-HCC occurs in the absence of cirrhosis. Areas covered: The epidemiology of NAFLD related HCC and its impac...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
Authors: Suk KT, Kim DJ Abstract INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is one of the most common and increasing liver diseases worldwide with a prevalence of 20-33%. NAFLD may progress to fibrosis, compensated cirrhosis, advanced cirrhosis, or hepatocellular carcinoma. Despite the increasing prevalence of NAFLD, definitive medical treatment has not been established, with the exception of lifestyle modification with exercise. Because of the direct connection via portal vein between the intestines and the liver (gut-gut microbiota-liver axis), gut microbiota and associated dysbiosis have been known a...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
Persistent injury of the hepatic tissue leads to fibrosis, which eventually evolves to cirrhosis, the end-stage of any chronic liver diseases. Cirrhosis is characterized by distortion of hepatic architecture, regenerative nodules and hepatocyte dysfunction and is associated with life-threatening complications such as hepatocellular insufficiency and hepatocellular carcinoma (HCC)[1]. Liver cirrhosis is estimated to cause around 170,000 deaths annually[2]. So far, liver transplantation represents the only curative therapeutic solution for many chronic liver diseases.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Research Article Source Type: research
Abstract Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease characterized by progressive fibroinflammatory destruction of the intra- and/or extrahepatic biliary ducts. While its features and disease course can be variable, most patients with PSC have concurrent inflammatory bowel disease and will eventually develop liver cirrhosis and end-stage liver disease, with liver transplantation representing the only potentially curative option. Importantly, PSC is associated with a significantly increased risk of malignancy compared to the general population, mainly cholangiocarcinoma, gallbladder car...
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research
This study is registered with ClinicalTrials.gov, number NCT01953458.FindingsBetween Aug 6, 2012, and Dec 31, 2015, 10 166 patients were eligible for the study. 9895 (97%) patients had available follow-up information and were included in analyses. Median follow-up was 33·4 months (IQR 24·0–40·7). Treatment with direct-acting antivirals was initiated during follow-up in 7344 patients, and 2551 patients remained untreated at the final follow-up visit. During follow-up, 218 patients died (129 treated, 89 untreated), 258 reported hepatocellular carcinoma (187 treated, 71 untreated), and 106 had dec...
Source: The Lancet - Category: General Medicine Source Type: research
More News: Biomedical Science | Cancer & Oncology | Carcinoma | Children | Cirrhosis | Hepatocellular Carcinoma | Laboratory Medicine | Liver | Liver Cancer | Liver Disease | Liver Transplant | Science | Transplants | UK Health | Urology & Nephrology